Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Kiyatec

News headline image
Kiyatec Secures Strategic Investment from South Korean Partner MBD to Accelerate U.S. Commercial Expansion
From Kiyatec
Via Business Wire
News headline image
Kiyatec Inc. Achieves Prestigious CAP Accreditation and New York State Approval for 3D Predict™
From Kiyatec
Via Business Wire
News headline image
Kiyatec Announces Publication of Groundbreaking Study on 3D Predict™ Glioma in High-Grade Glioma (HGG) Patients
From Kiyatec
Via Business Wire
News headline image
Kiyatec Appoints Eric Perreault as New CEO to Lead Strategic Expansion
From Kiyatec
Via Business Wire
News headline image
Kiyatec strengthens its leadership position with the addition of Mark Capone, former CEO of Myriad Genetics, as Strategic Advisor
From Kiyatec
Via Business Wire
News headline image
Kiyatec Appoints Eric Perreault to President and Appoints Tessa DesRochers, PhD, Chief Scientific Officer to Vice President of Pre-Clinical Services
From Kiyatec
Via Business Wire
News headline image
Kiyatec and XenoSTART formally announce a collaborative agreement to help reduce drug development costs by providing correlative ex vivo efficacy data using Kiyatec’s 3D spheroid screening platform, KIYA-Predict™
From Kiyatec
Via Business Wire
News headline image
Kiyatec and AstraZeneca Announce a Multifaceted Research Agreement to Generate Novel Preclinical Data Using Kiyatec’s 3D Spheroid Screening Platform, KIYA-PredictTM
From Kiyatec
Via Business Wire
News headline image
Kiyatec to present two posters highlighting the company’s work in ex vivo immuno-oncology at the 2023 AACR Annual Meeting April 14-19, in Orlando, FL
From Kiyatec
Via Business Wire
News headline image
Kiyatec CEO Matt Gevaert joins biopharma leaders and healthcare investor discussions at Longwood Healthcare Leaders Fall Webconference
From Kiyatec
Via Business Wire
News headline image
Kiyatec to Sponsor and Exhibit at the Virtual American Brain Tumor Association 2022 National Conference September 9-10, 2022
From Kiyatec
Via Business Wire
News headline image
Kiyatec Announces New Clinical Evidence in High Grade Glioma Accepted for Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) 2022
From Kiyatec
Via Business Wire
News headline image
CORRECTING and REPLACING KIYATEC and ACCRF Joint Abstract at AACR Highlights Use of KIYA-PREDICT™ Drug Response Platform in ACC
From KIYATEC
Via Business Wire
News headline image
KIYATEC and AACR Joint Abstract at AACR Highlights Use of KIYA-PREDICT™ Drug Response Platform in ACC
From KIYATEC
Via Business Wire
News headline image
KIYATEC to Present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum
From KIYATEC
Via Business Wire
News headline image
KIYATEC Announces Key Appointments in Market Access & Reimbursement and Business Development Roles
From KIYATEC
Via Business Wire
News headline image
KIYATEC to Present New Clinical Correlation Data at American Association for Cancer Research
From KIYATEC
Via Business Wire
News headline image
KIYATEC Chooses Downtown Greenville for Major Operations Expansion
From KIYATEC
Via Business Wire
News headline image
KIYATEC Announces Addition of Chief Commercial Officer Stacy Chick to Executive Team
From KIYATEC
Via Business Wire
News headline image
KIYATEC Marks Glioblastoma Awareness Day by Initiating Use of 3D Predict™ Glioma Test Outside of Clinical Study
From KIYATEC
Via Business Wire
News headline image
KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors
From KIYATEC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.